Моногенные аутовоспалительные синдромы с чертами системных васкулитов: новая область ревматологии
https://doi.org/10.47360/1995-4484-2023-458-465
Аннотация
Обзор посвящен новой актуальной проблеме ревматологии – моногенным аутовоспалительным синдромам с чертами системных васкулитов, которые могут манифестировать во взрослом возрасте. Рассматриваются особенности клинического течения редко диагностируемого синдрома VEXAS, а также встречающихся иногда у взрослых синдромов SAVI и СОРА. Обсуждаются перспективные направления лечения будущего.
Ключевые слова
синдром VEXAS,
синдром SAVI,
синдром,
СОРА,
системный васкулит,
моногенный аутовоспалительный синдром,
васкулопатия
Об авторах
Т. В. Бекетова
ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации; ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Московский политехнический университет»
Россия
Россия
д.м.н., зав.отделением «ревматологии с нефрологическими койками и кабинетом терапии ГИБП» ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации, ведущий научный сотрудник лаборатории «микроциркуляции и воспаления» ФГБНУ НИИР им. В.А. Насоновой, профессор кафедры «инфокогнитивные технологии» факультета информационных технологий ФГАОУ ВО «Московский политехнический университет»
121356, Москва, ул. Маршала Тимошенко, 15
115522, Москва, Каширское шоссе, 34а
107023, Москва, ул. Большая Семёновская, 38
М. Ф. Бекетова
ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»
Россия
Россия
клинический ординатор кафедры «внутренних болезней» факультета фундаментальной медицины
119234, Москва, Ленинские горы, 1
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова»
Минздрава России (Сеченовский Университет)
Россия
Россия
д.м.н, профессор, академик РАН, научный руководитель
115522, Москва, Каширское шоссе, 34а
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Demir S, Sag E, Dedeoglu F, Ozen S. Vasculitis in systemic autoinflammatory diseases. Front Pediatr. 2018;6:377. doi: 10.3389/fped.2018.00377
2. Салугина СО, Федоров ЕС, Агафонова ЕМ. Моногенные аутовоспалительные заболевания у детей и взрослых: что необходимо знать ревматологу. Научно-практическая ревматология. 2019;57(2):125-132. [Salugina SO, Fedorov ES, Agafonova EM. Monogenic auto-inflammatory diseases in children and adults: What a rheumatologist should know. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(2):125-132 (In Russ.)]. doi: 10.14412/1995-4484-2019-125-132
3. Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137(26):3591-3594. doi: 10.1182/blood.2021011455
4. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628-2638. doi: 10.1056/NEJMoa2026834
5. Arlet JB, Terrier B, Kosmider O. Mutant UBA1 and severe adultonset autoinflammatory disease. N Engl J Med. 2021;22:2163. doi: 10.1056/NEJMc2102124
6. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24-64. doi: 10.1007/s10875-019-00737-x
7. Barba T, Jamilloux Y, Durel CA, Bourbon E, Mestrallet F, Sujobert P, et al. VEXAS syndrome in a woman. Rheumatology (Oxford). 2021;60(11):e402-e403. doi: 10.1093/rheumatology/keab392
8. Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO, et al.Nevill TJ. VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica. 2022;107(4):1011-1013. doi: 10.3324/haematol.2021.280238
9. Rasch MNB, Szabados F, Jensen JMB, Nielsen KO, Hauge EM, Troldborg A. Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers. RMD Open. 2022;8(2):e002492. doi: 10.1136/rmdopen-2022-002492
10. Templé M, Kosmider O. VEXAS syndrome: A novelty in MDS landscape. Diagnostics (Basel). 2022;12(7):1590. doi: 10.3390/diagnostics12071590
11. Watanabe R, Kiji M, Hashimoto M. Vasculitis associated with VEXAS syndrome: A literature review. Front Med (Lausanne). 2022;9:983939. doi: 10.3389/fmed.2022.983939
12. Beck DB, Werner A, Kastner DL, Aksentijevich I. Disorders of ubiquitylation: Unchained inflammation. Nat Rev Rheumatol. 2022;18(8):435-447. doi: 10.1038/s41584-022-00778-4
13. Muratore F, Marvisi C, Castrignanò P, Nicoli D, Farnetti E, Bonanno O, et al. VEXAS syndrome: A case series from a singlecenter cohort of Italian patients with vasculitis. Arthritis Rheumatol. 2022;74(4):665-670. doi: 10.1002/art.41992
14. Stubbins RJ, Cherniawsky H, Chen LYC, Nevill TJ. Innovations in genomics for undiagnosed diseases: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. CMAJ. 2022;194(14):E524-E527. doi: 10.1503/cmaj.211770
15. Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol. 2021;73(10):1886-1895. doi: 10.1002/art.41743
16. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al.; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Further characterization of clinical and laboratory features in VEXAS syndrome: Large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564-574. doi: 10.1111/bjd.20805
17. van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022;149(1): 432-439.e4. doi: 10.1016/j.jaci.2021.05.014
18. Comont T, Heiblig M, Rivière E, Terriou L, Rossignol J, Bouscary D, et al.; French VEXAS study group, Groupe Francophone des Myélodysplasies (GFM) and MedecineINterne, HEmato et ONco (MINHEMON) group. Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: Data from the French VEXAS registry. Br J Haematol. 2022;196(4):969-974. doi: 10.1111/bjh.17893
19. Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: A 2-center experience. Blood Adv. 2022;6(3):998-1003. doi: 10.1182/bloodadvances. 2021004749
20. Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N, et al. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: A case report. Bone Marrow Transplant. 2022;57(2):315-318. doi: 10.1038/s41409-021-01544-y
21. A phase II study of allogeneic hematopoietic stem cell transplant for subjects with VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. ClinicalTrials.gov. NCT05027945. URL: https://clinicaltrials.gov/ct2/show/NCT05027945 (Accessed: 8th July 2023).
22. Campochiaro C, Tomelleri A, Cavalli G, De Luca G, Grassini G, Cangi MG, et al. Successful use of cyclosporine A and interleukin- 1 blocker combination therapy in VEXAS syndrome: A singlecenter case series. Arthritis Rheumatol. 2022;74(7):1302-1303. doi: 10.1002/art.42101
23. Goyal A, Narayanan D, Wong W, Laga AC, Connell NT, Ritter SY, et al. Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. JAAD Case Rep. 2022;23:15-19. doi: 10.1016/j.jdcr.2022.02.022
24. Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: A retrospective multicenter study. Blood. 2022;140(8):927-931. doi: 10.1182/blood.2022016642
25. Wan R, Fänder J, Zakaraia I, Lee-Kirsch MA, Wolf C, Lucas N, et al. Phenotypic spectrum in recessive STING-associated vasculopathy with onset in infancy: Four novel cases and analysis of previously reported cases. Front Immunol. 2022;13:1029423. doi: 10.3389/fimmu.2022.1029423
26. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507-518. doi: 10.1056/NEJMoa1312625
27. David C, Frémond ML. Lung Inflammation in STING-associated vasculopathy with onset in infancy (SAVI). Cells. 2022;11(3):318. doi: 10.3390/cells11030318
28. Staels F, Betrains A, Doubel P, Willemsen M, Cleemput V, Vanderschueren S, et al. Adult-onset ANCA-associated vasculitis in SAVI: Extension of the phenotypic spectrum, case report and review of the literature. Front Immunol. 2020;11:575219. doi: 10.3389/fimmu.2020.575219
29. Wang Y, Wang F, Zhang X. STING-associated vasculopathy with onset in infancy: A familial case series report and literature review. Ann Transl Med. 2021;9(2):176. doi: 10.21037/atm-20-6198
30. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516-5520. doi: 10.1172/JCI79100
31. Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65-e71. doi: 10.1016/j.chest.2016.02.682
32. Watkin LB, Jessen B, Wiszniewski W, Vece TJ, Jan M, Sha Y, et al.; COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet. 2015;47(6):654-660. doi: 10.1038/ng.3279
33. Vece TJ, Watkin LB, Nicholas S, Canter D, Braun MC, Guillerman RP, et al. COPA syndrome: A novel autosomal dominant immune dysregulatory disease. J Clin Immunol. 2016;36(4):377-387. doi: 10.1007/s10875-016-0271-8
34. Taveira-DaSilva AM, Markello TC, Kleiner DE, Jones AM, Groden C, Macnamara E, et al. Expanding the phenotype of COPA syndrome: A kindred with typical and atypical features. J Med Genet. 2019;56(11):778-782. doi: 10.1136/jmedgenet-2018-105560
35. Jensson BO, Hansdottir S, Arnadottir GA, Sulem G, Kristjansson RP, Oddsson A, et al. COPA syndrome in an Icelandic family caused by a recurrent missense mutation in COPA. BMC Med Genet. 2017;18(1):129. doi: 10.1186/s12881-017-0490-8
36. Patel JH, Buzard KL, Israel HA. Presentation of COPA syndrome in an adult: A newly described primary immunodeficiency. Seattle, WA:American College of Allergy, Asthma & Immunology;2018.
37. Beshay S, Osuna I, Smith J, Branch J, Muruato L, DeGuzman M, et al. COPA syndrome-associated mutations in lung transplant recipients for interstitial lung disease. Arthritis Rheumatol. 2021;73(Suppl 9). URL: https://acrabstracts.org/abstract/copasyndrome-associated-mutations-in-lung-transplant-recipientsfor-interstitial-lung-disease (Accessed: 8th July 2023).
38. Lepelley A, Martin-Niclós MJ, Le Bihan M, Marsh JA, Uggenti C, Rice GI, et al. Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. J Exp Med. 2020;217(11):e20200600. doi: 10.1084/jem.20200600
39. Steiner A, Hrovat-Schaale K, Prigione I, Yu CH, Laohamonthonkul P, Harapas CR, et al. Deficiency in coatomer complex I causes aberrant activation of STING signalling. Nat Commun. 2022;13(1):2321. doi: 10.1038/s41467-022-29946-6
40. Deng Z, Chong Z, Law CS, Mukai K, Ho FO, Martinu T, et al. A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome. J Exp Med. 2020;217(11): e20201045. doi: 10.1084/jem.20201045
41. Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol. 2018;187:33-36. doi: 10.1016/j.clim.2017.10.001
42. Patwardhan A, Spencer CH. An unprecedented COPA gene mutation in two patients in the same family: Comparative clinical analysis of new ly reported patients with other known COPA gene mutations. Pediatr Rheumatol Online J. 2019;17(1):59. doi: 10.1186/s12969-019-0359-9
43. Krutzke S, Rietschel C, Horneff G. Baricitinib in therapy of COPA syndrome in a 15-year-old girl. Eur J Rheumatol. 2019;7(Suppl 1): 1-4. doi: 10.5152/eurjrheum.2019.18177
44. Frémond ML, Legendre M, Fayon M, Clement A, Filhol-Blin E, Richard N, et al. Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage. Thorax. 2020;75(1): 92-95. doi: 10.1136/thoraxjnl-2019-213892
45. Doroudchi A, Butte M. First reported use of anifrolumab to treat a monogenic interferonopathy (DNASE2 loss of function). Clin Immunol. 2023;250. doi: 10.1016/j.clim.2023.109593
Рецензия
Для цитирования:
Бекетова Т.В., Бекетова М.Ф., Насонов Е.Л. Моногенные аутовоспалительные синдромы с чертами системных васкулитов: новая область ревматологии. Научно-практическая ревматология. 2023;61(4):458-465. https://doi.org/10.47360/1995-4484-2023-458-465
For citation:
Beketova T.V., Beketova M.F., Nasonov E.L. Monogenic autoinflammatory syndromes with features of systemic vasculitis: a new field of rheumatology. Rheumatology Science and Practice. 2023;61(4):458-465. (In Russ.) https://doi.org/10.47360/1995-4484-2023-458-465
Просмотров: 305
Послать статью по эл. почте 